Cerevel Therapeutics stock ticks higher amid Nasdaq delisting notice for AbbVie deal
About 67% of Cerevel Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Cerevel Therapeutics Holdings suggests that many traders are alarmed regarding Cerevel Therapeutics' prospects. The current market sentiment, together with Cerevel Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Cerevel Therapeutics stock news signals to limit their universe of possible portfolio assets.
Cerevel |
Cerevel Therapeutics sees slight increase in premarket trading following Nasdaq delisting notice amidst AbbVie acquisition news.
Read at seekingalpha.com
Cerevel Therapeutics Fundamental Analysis
We analyze Cerevel Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cerevel Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cerevel Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
Cerevel Therapeutics is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Cerevel Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cerevel Therapeutics stock to make a market-neutral strategy. Peer analysis of Cerevel Therapeutics could also be used in its relative valuation, which is a method of valuing Cerevel Therapeutics by comparing valuation metrics with similar companies.
Peers
Cerevel Therapeutics Related Equities
IGMS | IGM Biosciences | 7.47 | ||||
MLYS | Mineralys Therapeutics, | 5.64 | ||||
DSGN | Design Therapeutics | 4.67 | ||||
APLS | Apellis Pharmaceuticals | 4.39 | ||||
TVTX | Travere Therapeutics | 4.04 | ||||
GPCR | Structure Therapeutics | 2.38 | ||||
BPMC | Blueprint Medicines | 1.29 | ||||
SWTX | SpringWorks Therapeutics | 0.94 | ||||
STOK | Stoke Therapeutics | 0.33 | ||||
DAWN | Day One | 0.65 | ||||
IKNA | Ikena Oncology | 1.16 | ||||
GLUE | Monte Rosa | 1.35 | ||||
TERN | Terns Pharmaceuticals | 1.44 | ||||
HOWL | Werewolf Therapeutics | 2.00 | ||||
CGEM | Cullinan Oncology | 2.08 | ||||
NUVL | Nuvalent | 2.49 | ||||
RNA | Avidity Biosciences | 4.02 | ||||
VTYX | Ventyx Biosciences | 5.97 | ||||
RVMD | Revolution Medicines | 10.46 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Consideration for investing in Cerevel Stock
If you are still planning to invest in Cerevel Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cerevel Therapeutics' history and understand the potential risks before investing.
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Stocks Directory Find actively traded stocks across global markets | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |